• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BlueTheory rebrands to BTC Network, launches new business model

BlueTheory rebrands to BTC Network, launches new business model

June 27, 2016
CenterWatch Staff

BlueTheory Clinical Trials, a clinical research network company headquartered in Boston, Massachusetts has been partnering with pharmaceutical and CROs to bring treatments and devices to the market since its inception. Based on increased demands from BlueTheory’s over 30 aligned pharmaceutical and CRO strategic partners, BlueTheory has enhanced its site business model and is announcing its rebrand to BTC Network.

BTC Network has optimized its infrastructure to an owned and affiliated research site model. The BTC Network team has completed over 300 clinical research studies across a range of therapeutic indications with the goal of expediting study startup and enrollment while ensuring our research sites provide excellent clinical oversight and good quality data. Today, BTC Network has grown to represent 63 full service, multi-specialty clinical research sites across the U.S. and Canada. BTC Network is currently in the final stages of acquiring two additional clinical research sites with other acquisitions on the near horizon.

With increased demands from Pharmaceutical companies and CROs for BTC Network to enroll all of the patients for their upcoming study protocols, BTC’s experienced team has worked to optimize research site performance by utilizing a number of cutting-edge resources. 

“By leveraging a number of centralized resources, all BTC Network sites have been able to streamline the start-up process and ultimately see faster rates of enrollment,” said Scott Palmese, director of Clinical Operations at BTC Network.

Alfred Peters, president at BTC Network, said, “Pharmaceutical companies and CROs do not have to view U.S. research facilities as a mom and pop industry. Our ability to offer centralized processes with one point of contact from start-up through enrollment for all of our sites with BTC Network¹s provided resources is critical to our success. Our resources include: contracts/budgets, receivable management, pharmaceutical relationship management, patient recruitment and retention, patient travel coordination, access to clinic patient populations, quality management team, centralized call center and many others. These resources put our research sites in the best possible position to understand therapeutic strengths and capabilities to exceed expectations on all clinical research studies.”

BTC Network works on behalf of leading pharmaceutical companies and CROs to excel in the identification, recruitment, and retention of patients. BTC Network’s number one focus is patient centricity. By working with BTC Network, sponsors and CROs have access to a fully integrated network of high performing and experienced sites with strong research infrastructures and access to large clinic populations, expediting enrollment.

Through the new BTC Network, sponsors will have access to:

  • One central point of contact for trial duration
  • Reporting on any deviations or patient enrollment challenges
  • Clinic and research patient databases of over 500,000 patients across North America
  • Centralized recruitment strategies and our ability to allocate resources as needed
  • One contract and budget for all sites

BTC Network’s partnerships throughout the industry and streamlined processes from study start-up to close-out will lead to more cost-effective, yet higher quality, research studies for the industry.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing